Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analyse the changes of A-H premium on 182 stocks over the last week. The average A-H premium was 72.3% as of May 22nd.</li>
<li>The average A-H premium changed by 0.4ppt week-on-week, led by health care, materials, real estate and offset by consumer staples, energy, communication services.</li>
<li>We highlight weekly changes in A-H premium for China Longyuan Power, Eastroc, CIMC, Remegen.</li>
</ul>


We analyse the changes of A-H premium on 182 stocks over the last week. The average A-H premium was 72.3% as of May 22nd.
The average A-H premium changed by 0.4ppt week-on-week, led by health care, materials, real estate and offset by consumer staples, energy, communication services.
We highlight weekly changes in A-H premium for China Longyuan Power, Eastroc, CIMC, Remegen.


A-H Premium Weekly (May 22nd): China Longyuan Power, Eastroc, CIMC, Remegen

<ul>
<li>We analyse the changes of A-H premium on 182 stocks over the last week. The average A-H premium was 71.9% as of May 15th.</li>
<li>The average A-H premium changed by 1.7ppt week-on-week, led by utilities, consumer staples, information technology and offset by communication services, consumer discretionary.</li>
<li>We highlight weekly changes in A-H premium for Datang Power, CIMC, Beone Medicines, Midea, Weichai Power, China Telecom.</li>
</ul>


We analyse the changes of A-H premium on 182 stocks over the last week. The average A-H premium was 71.9% as of May 15th.
The average A-H premium changed by 1.7ppt week-on-week, led by utilities, consumer staples, information technology and offset by communication services, consumer discretionary.
We highlight weekly changes in A-H premium for Datang Power, CIMC, Beone Medicines, Midea, Weichai Power, China Telecom.


A-H Premium Weekly (May 15th): Datang Power, CIMC, Beone Medicines, Midea, Weichai Power

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Lupeng Pharmaceutical / Equity Capital Markets

<ul>
<li>The product that best represents Lupeng's breakthrough proposition from numerous pipelines would undoubtedly be LP-168, whose unique development path has the opportunity to gain market attention. </li>
<li>How much market LP-168 is able to seize from existing players is highly uncertain. Since LP-108/LP-118 are in early clinical stage, there's a possibility of R&amp;D failure in the future.</li>
<li>Post-Money valuation after Series B Financing was US$311.25mn. Since Lupeng has no commercialized products on the market, its valuation would be lower than peers such as BeiGene, Innocare and Ascentage.</li>
</ul>


The product that best represents Lupeng's breakthrough proposition from numerous pipelines would undoubtedly be LP-168, whose unique development path has the opportunity to gain market attention. 
How much market LP-168 is able to seize from existing players is highly uncertain. Since LP-108/LP-118 are in early clinical stage, there's a possibility of R&amp;D failure in the future.
Post-Money valuation after Series B Financing was US$311.25mn. Since Lupeng has no commercialized products on the market, its valuation would be lower than peers such as BeiGene, Innocare and Ascentage.


Pre-IPO Lupeng Pharmaceutical - Unique Pipeline May Not Guarantee the Commercialization Outlook

<ul>
<li>We analyse the changes of A-H premium on 170 stocks over the last week. The average A-H premium was 65.2% as of Feb 13th.</li>
<li>The average A-H premium changed by -2.8ppt week-on-week, led by consumer staples, utilities, industrials and offset by communication services.</li>
<li>We highlight weekly changes in A-H premium for Shanghai Electric, China Energy Engineering, Sinotrans, BYD, Flat Glass, Zijin Mining.</li>
</ul>


We analyse the changes of A-H premium on 170 stocks over the last week. The average A-H premium was 65.2% as of Feb 13th.
The average A-H premium changed by -2.8ppt week-on-week, led by consumer staples, utilities, industrials and offset by communication services.
We highlight weekly changes in A-H premium for Shanghai Electric, China Energy Engineering, Sinotrans, BYD, Flat Glass, Zijin Mining.


A-H Premium Weekly (Feb 13th): Shanghai Electric, China Energy Engineering, Sinotrans, BYD

<ul>
<li>We analyse the changes of A-H premium on 169 stocks over the last week. The average A-H premium was 58.5% as of Jan 23rd.</li>
<li>The average A-H premium changed by -3.0ppt week-on-week, led by information technology, energy, materials and offset by financials, health care.</li>
<li>We highlight weekly changes in A-H premium for Chifeng Jilong Gold Mining, Flat Glass, Maanshan Iron &amp; Steel, China Tourism, Sinopec, Sany Heavy.</li>
</ul>


We analyse the changes of A-H premium on 169 stocks over the last week. The average A-H premium was 58.5% as of Jan 23rd.
The average A-H premium changed by -3.0ppt week-on-week, led by information technology, energy, materials and offset by financials, health care.
We highlight weekly changes in A-H premium for Chifeng Jilong Gold Mining, Flat Glass, Maanshan Iron &amp; Steel, China Tourism, Sinopec, Sany Heavy.


A-H Premium Weekly (Jan 23rd): Chifeng Jilong Gold Mining, Flat Glass, Maanshan Iron & Steel

China

InnoCare Pharma is a commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing drugs for cancer and autoimmune diseases. Its pipeline includes key products like orelabrutinib, tafasitamab, and ICP-332. The company was co-founded in 2015 and is headquartered in Beijing, China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

InnoCare Pharma (9969 HK)

A-H Premium Weekly (May 22nd): China Longyuan Power, Eastroc, CIMC, Remegen

We analyzed A-H premium changes in the past week and highlight A-H premium changes for China Longyuan Power, Eastroc, CIMC, Remegen.

Ke Yan, CFA, FRM

A-H Premium Weekly (May 15th): Datang Power, CIMC, Beone Medicines, Midea, Weichai Power

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Datang Power, CIMC, Beone Medicines, Midea, Weichai Power,...

Ke Yan, CFA, FRM

Pre-IPO Lupeng Pharmaceutical - Unique Pipeline May Not Guarantee the Commercialization Outlook

Lupeng's LP-168 shows promise but faces uncertainty in market competition. LP-108 and LP-118 are in early clinical stage with high R&D failure...

Xinyao (Criss) Wang

A-H Premium Weekly (Feb 13th): Shanghai Electric, China Energy Engineering, Sinotrans, BYD

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Shanghai Electric, China Energy Engineering, Sinotrans, BYD,...

Ke Yan, CFA, FRM

A-H Premium Weekly (Jan 23rd): Chifeng Jilong Gold Mining, Flat Glass, Maanshan Iron & Steel

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Chifeng Jilong Gold Mining, Flat Glass, Maanshan Iron &...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

A-H Premium Weekly (May 22nd): China Longyuan Power, Eastroc, CIMC, Remegen

We analyzed A-H premium changes in the past week and highlight A-H premium changes for China Longyuan Power, Eastroc, CIMC, Remegen.

Ke Yan, CFA, FRM

A-H Premium Weekly (May 15th): Datang Power, CIMC, Beone Medicines, Midea, Weichai Power

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Datang Power, CIMC, Beone Medicines, Midea, Weichai Power,...

Ke Yan, CFA, FRM

Pre-IPO Lupeng Pharmaceutical - Unique Pipeline May Not Guarantee the Commercialization Outlook

​Lupeng's LP-168 shows promise but faces uncertainty in market competition. LP-108 and LP-118 are in early clinical stage with high R&D failure...

Xinyao (Criss) Wang

A-H Premium Weekly (Feb 13th): Shanghai Electric, China Energy Engineering, Sinotrans, BYD

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Shanghai Electric, China Energy Engineering, Sinotrans, BYD,...

Ke Yan, CFA, FRM

A-H Premium Weekly (Jan 23rd): Chifeng Jilong Gold Mining, Flat Glass, Maanshan Iron & Steel

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Chifeng Jilong Gold Mining, Flat Glass, Maanshan Iron &...

Ke Yan, CFA, FRM

Lupeng's LP-168 shows promise but faces uncertainty in market competition. LP-108 and LP-118 are in early clinical stage with high R&D failure...